• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SWTX

    SpringWorks Therapeutics Inc.

    Subscribe to $SWTX
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: springworkstx.com

    Peers

    $ALLO

    Recent Analyst Ratings for SpringWorks Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    See more ratings

    SpringWorks Therapeutics Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by SpringWorks Therapeutics Inc.

      SCHEDULE 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      5/7/25 11:01:53 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 4:02:03 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 6:02:57 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 6:01:49 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/4/25 4:06:27 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by SpringWorks Therapeutics Inc.

      DEF 14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/4/25 4:05:24 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by SpringWorks Therapeutics Inc.

      S-8 - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      2/20/25 7:01:06 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by SpringWorks Therapeutics Inc.

      10-K - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      2/20/25 6:51:04 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      2/20/25 6:48:38 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by SpringWorks Therapeutics Inc.

      144 - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/25 4:21:37 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    SpringWorks Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      10/25/24 9:46:32 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 6:41:08 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 8:56:14 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/13/24 5:14:03 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/9/24 9:49:30 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      1/26/24 11:49:42 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      1/23/24 10:22:49 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13D/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      12/6/23 4:43:33 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13D/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      5/17/23 4:46:59 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by SpringWorks Therapeutics Inc.

      SC 13G - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      4/14/23 4:35:21 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    SpringWorks Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      – Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in

      4/28/25 2:13:33 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 billion Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for the Healthcare business of Merck KGaA, Darmstadt, Germany SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, i

      4/28/25 2:11:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

      STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases an

      4/27/25 10:35:13 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

      2/20/25 6:30:32 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

      - Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn., Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor. Desmoid tumors ar

      2/19/25 8:00:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

      – GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9https

      2/11/25 8:20:22 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

      – GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4

      2/11/25 5:27:40 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

      STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

      1/30/25 7:00:50 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

      – Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Ended 2024 with approximately $462 million in cash, cash equivalents, and marketable securities – – Additional updates across Company's commercial portfolio and investigational pipeline to be provided during J.P. Morgan Healthcare conference presentation today at 11:15 a.m. PT – STAMFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced its preliminary fourth quarter and full year 2024 U.

      1/13/25 6:30:33 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company's website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks' website for a limited time following the conference. About SpringWorks Therapeutics SpringWorks is a commercial

      1/3/25 6:30:46 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    SpringWorks Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Edris Badreddin sold $1,084,592 worth of shares (20,000 units at $54.23), decreasing direct ownership by 11% to 169,712 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:33:49 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib covered exercise/tax liability with 30,756 shares and sold $2,657,656 worth of shares (49,000 units at $54.24), decreasing direct ownership by 8% to 954,869 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:32:29 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib sold $1,768,401 worth of shares (29,328 units at $60.30), decreasing direct ownership by 3% to 1,034,625 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:58:58 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Ashar Bhavesh sold $62,168 worth of shares (1,016 units at $61.19), decreasing direct ownership by 2% to 62,053 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:58:02 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lynch Daniel sold $2,866,534 worth of shares (47,600 units at $60.22), decreasing direct ownership by 36% to 82,944 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:57:12 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib sold $639,490 worth of shares (10,672 units at $59.92), decreasing direct ownership by 0.99% to 1,063,953 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/19/25 4:50:33 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lynch Daniel sold $24,000 worth of shares (400 units at $60.00), decreasing direct ownership by 0.31% to 130,544 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/19/25 4:49:19 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib was granted 85,309 shares and covered exercise/tax liability with 13,186 shares, increasing direct ownership by 7% to 1,074,625 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/14/25 7:30:20 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief People Officer Pichl Daniel exercised 29,750 shares at a strike of $27.64 and sold $1,617,329 worth of shares (29,750 units at $54.36) (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/12/25 8:01:39 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lynch Daniel sold $9,530,351 worth of shares (175,000 units at $54.46), decreasing direct ownership by 57% to 130,944 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/12/25 7:59:41 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    SpringWorks Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

      Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00

      11/20/24 8:20:27 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SpringWorks Therapeutics with a new price target

      Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00

      2/5/24 8:04:18 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on SpringWorks Therapeutics with a new price target

      BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00

      12/1/22 7:57:05 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan reiterated coverage on SpringWorks Therapeutics with a new price target

      JP Morgan reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $105.00 from $97.00 previously

      9/8/21 8:36:12 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on SpringWorks Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $137.00 from $136.00 previously

      8/5/21 6:47:30 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman Sachs resumed coverage on SpringWorks Therapeutics with a new price target

      Goldman Sachs resumed coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $112.00

      3/22/21 7:36:22 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright reiterated coverage on SpringWorks Therapeutics with a new price target

      HC Wainwright reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $124.00 from $101.00 previously

      3/3/21 8:12:18 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on SpringWorks Therapeutics with a new price target

      Barclays reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $105.00 from $92.00 previously

      2/26/21 7:31:16 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on SpringWorks Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $124.00 from $101.00 previously

      2/25/21 10:26:55 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on SpringWorks Therapeutics

      Barclays reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $92 from $83 previously

      1/22/21 8:50:15 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    SpringWorks Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    SpringWorks Therapeutics Inc. Financials

    Live finance-specific insights

    See more

    SpringWorks Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

      For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

      11/27/23 5:34:21 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

      Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

      11/27/23 5:34:04 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

      2/20/25 6:30:32 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

      STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

      1/30/25 7:00:50 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

      11/12/24 6:30:21 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

      STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be availa

      10/22/24 7:00:14 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      – Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the second quarter of 2024 and provided an update

      8/7/24 6:30:35 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

      STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be availa

      7/23/24 7:00:02 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported first quarter financial results for the period ended March 31, 2024 and

      5/2/24 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

      STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To access the live call by phone, please pre-register for the call by clicking here. Once registration is complete, participants will be provided with a dial-in number and conference code to access the call. A replay of the webcast will

      4/18/24 7:00:28 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

      – Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – – SpringWorks to host conference call tomorrow at 8:00 a.m. ET – A Media Snippet accompanying this announcement is available by clicking on this link. STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved OGSIVEO™ (nirogacestat), a

      11/27/23 6:04:15 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

      – Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable responses and significant improvements in key secondary patient-reported outcome measures – – Mirdametinib was generally well tolerated with low rates of Grade 3+ adverse events – – Additional data expected to be presented at medical conference and NDA submission to the U.S. FDA planned in the first half of 2024 – – Company to host conference call today at 8:30 a.m. Eastern Time – STAMFORD, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-st

      11/16/23 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

      STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

      7/29/24 6:30:11 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

      STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

      9/11/23 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

      STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

      7/15/22 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilgamesh Builds Team of Pharmaceutical Industry Leaders and Appoints New Members to Board of Directors

      NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a mental health focused biotechnology company developing novel psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the addition of several key additions to its leadership team and board of directors. The additions will enable Gilgamesh to rapidly advance its pipeline toward clinical trials beginning in late 2022 and further expand its IP portfolio. Key hires include: Chief Medical Officer Gerard Marek, MD/Ph.D. is a renowned expert on serotonin system biology. Gerard is a former asst. professor at Yale University and was the Chief Scientific Officer of Psychiatric Disorders Discove

      11/11/21 9:00:00 AM ET
      $BHVN
      $SWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development

      STAMFORD, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development (R&D). Dr. Burgess is a physician-scientist with clinical experience in pediatrics and pediatric oncology and over 20 years of pharmaceutical industry R&D leadership experience across several therapeutic areas, including oncology. Dr. Burgess will lead the R&D organization as the company continues to advance its diversified targeted oncology pipeline and t

      5/10/21 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care